Dive Brief:
- FDA approved Esai’s Aloxi for prevention of chemotherapy-induced nausea and vomiting (CINV) in children.
- Indication covers children between the ages of one month and 17 years.
- Aloxi is the first drug approved for treatment of acute CINV in infants between ages one month and six months.
Dive Insight:
Aloxi was compared with the standard of care, odansetron, and was deemed non-inferior (59.4% of Aloxi-treated patients had a complete response versus 58.6% of odansetron-treated patients). However, while odansetron requires an initial infusion, followed by two follow-ups, Aloxi requires one infusion based on treatment guidelines.